Introduction
Phage display is a powerful technique discovered over thirty years ago. Since then, a variety of phages have been investigated for their utility. Most notable among these are the Ff filamentous phage family, lambda phage, T4 phage, and T7 phage.
The Ff filamentous phage family is often preferred for its lysogenic life cycle. Lambda, T4 and T7 phage rely on bacterial lysis to release new phage particles. Meanwhile, Ff filamentous phage introduce their DNA directly into the bacterial genome. This results in the secretion of newly synthesised phage from the bacterium. This greatly simplifies the process of panning by eliminating the requirement to re-infect bacterial cells for amplification of selected phages.
The Ff filamentous phage family includes f1, fd, and M13 phages, all of which infect E. coli strains expressing the F pilus.
Today, phage display has become one of the most widely used technologies in antibody discovery, protein engineering, epitope mapping, and drug development. By enabling researchers to screen vast libraries of peptides, proteins, and antibody fragments against a target of interest, phage display can accelerate the identification of high-affinity binders for research, diagnostic, and therapeutic applications.
Why Does This Matter?
For scientists and biotechnology companies developing antibodies, diagnostics, or therapeutic candidates, identifying molecules with the required specificity and performance characteristics can be challenging. Phage display provides a powerful platform for rapidly screening billions of candidates, helping researchers accelerate discovery programmes and make more informed development decisions.
What is Phage Display?
Phage display is a laboratory technique that uses bacteriophages to display peptides, proteins, or antibody fragments on their surface. It allows researchers to identify molecules that bind to a target of interest by screening large libraries of variants.
The DNA sequence encoding the protein of interest is inserted into a phage coat protein gene. As the phage replicates, the encoded protein is displayed on the surface of the viral particle whilst the corresponding genetic information remains contained within the phage genome.
This direct link between displayed protein and encoding DNA allows researchers to rapidly identify molecules with desired binding characteristics through iterative selection processes known as biopanning.
Why is Phage Display Important for Antibody Discovery?
Phage display is widely used in antibody discovery because it enables researchers to screen billions of antibody variants and rapidly identify candidates with high affinity and specificity for a target antigen.
Unlike traditional hybridoma approaches, phage display allows antibody selection to take place entirely in vitro. This provides researchers with greater flexibility during screening and optimisation whilst supporting the discovery of antibodies against a wide range of targets.
The technology has become a cornerstone of modern antibody engineering and has contributed to the development of numerous therapeutic antibody candidates.
Why Does This Matter?
For biotechnology companies developing antibodies for research, diagnostic, or therapeutic applications, identifying the right antibody candidate is often one of the most critical stages of development.
Phage display helps reduce this challenge by allowing researchers to evaluate vast numbers of potential binders simultaneously, increasing the likelihood of identifying candidates with the required specificity and performance characteristics.
A Brief History of Phage Display
Phage display was first described by George P. Smith in 1985, when foreign peptides were successfully displayed on filamentous bacteriophage surfaces.
In 1990, McCafferty and colleagues demonstrated antibody phage display by expressing antibody fragments on filamentous phages. This landmark study showed that antibody libraries could be screened entirely in vitro, opening new possibilities for recombinant antibody discovery.
The significance of phage display was recognised in 2018 when George P. Smith and Sir Gregory Winter were awarded the Nobel Prize in Chemistry for their contributions to phage display and antibody engineering.
“Phage display transformed antibody engineering by enabling entirely in vitro selection of antibodies.” – Sir Gregory Winter
How Does Phage Display Work?
The phage display process begins with the construction of a library containing a large number of peptide, protein, or antibody variants.
These variants are displayed on the surface of bacteriophages and exposed to an immobilised target molecule. Phages displaying molecules with affinity for the target bind, whilst non-binding phages are removed through washing steps.
The bound phages are then recovered and amplified in bacterial cells before undergoing additional rounds of selection. Through repeated enrichment cycles, phages displaying the highest-affinity binders become increasingly dominant within the population.
The final selected clones can then be sequenced and characterised for downstream applications.
Why Does This Matter?
The ability to repeatedly enrich for the strongest binders allows researchers to rapidly narrow billions of potential candidates down to a small number of promising molecules for further evaluation.
This can significantly reduce the time and resources required during early-stage discovery programmes.
Types of Phage Display Systems
Irrespective of whichever phage is chosen, phage coat proteins are most commonly exploited as fusion partners for phage display. However, the selection of a suitable coat protein for a specific phage display application requires careful consideration.
M13 Filamentous Phage
All five coat proteins of the M13 phage have been used as fusion partners for phage display. Out of all of these, the major coat protein pVIII has been shown to enhance detection signal by virtue of its high abundance. However, it has been found that fusing pVIII with peptides greater than 6–8 residues in length results in poor coat protein assembly. It can also contribute to a loss of function.
As such, most peptides and folded proteins are instead displayed as fusions with pIII. As well as being amenable to the insertion of larger protein sequences than pVIII, a further advantage of pIII is that it allows for monovalent display (display of just a single copy of the foreign protein), enabling the selection of high-affinity binding partners.
The M13 phage has a single-stranded DNA genome and a capsid composed of five different coat proteins. These are the major capsid protein pVIII, which makes up the phage body, and the minor capsid proteins pIII, pVI, pVII and pIX, which are found at the ends of the phage.
Image from Cusabio’s website
M13 phage structure.[EE1] The M13 phage has a ssDNA genome and a capsid composed of five different coat proteins. These are the major capsid protein pVIII which makes up the phage body, and the minor capsid proteins pIII, pVI, pVII and pIX, which are found at the ends of the phage.
Lambda, T4, and T7 phage all vary from M13 in terms of size, structure and composition. Moreover, they lend themselves to different phage display applications depending on how they are used. For instance, the T4 proteins HOC and SOC can be used for simultaneous display of two different proteins on the phage surface. Whereas the T7 phage exhibits high stability under conditions which may inactivate other phages. While lambda phage is well-suited to display complex, high molecular weight proteins as fusions with the pD head protein or pV tail protein.
Lambda Phage
Lambda phage differs significantly from M13 in terms of size, structure and composition.
Lambda phage is particularly well suited to displaying complex, high molecular weight proteins as fusions with either the pD head protein or pV tail protein.
T4 Phage
The T4 proteins HOC and SOC can be used for simultaneous display of two different proteins on the phage surface. This creates opportunities for more advanced engineering strategies and specialised applications.
T7 Phage
The T7 phage exhibits high stability under conditions which may inactivate other phages. This makes it useful for applications requiring more robust screening conditions.
Comparison of Common Phage Display Systems
| System | Key Advantage | Typical Applications |
| M13 | Easy amplification and antibody display | Antibody discovery, peptide libraries |
| Lambda | Suitable for larger proteins | Complex protein display |
| T4 | Simultaneous display of multiple proteins | Protein engineering |
| T7 | High stability | Challenging screening conditions |
Why Does This Matter?
Choosing the most appropriate phage system can influence library construction, screening efficiency, and the types of molecules that can be displayed successfully.
Understanding the strengths and limitations of each system can help researchers select the most suitable platform for their application
Phage Display Libraries
The power of phage display lies in the diversity of the libraries that can be screened.
Naïve Libraries
Naïve libraries are constructed from antibody genes obtained from non-immunised donors. These libraries provide broad diversity and can be used to identify antibodies against a wide range of targets.
Immune Libraries
Immune libraries are generated from immunised animals or individuals exposed to a specific antigen. Because these libraries contain affinity-matured antibody repertoires, they often yield high-affinity binders against the target of interest.
Synthetic Libraries
Synthetic libraries are generated using rationally designed antibody frameworks and engineered diversity. Advances in synthetic biology have made these libraries increasingly popular for therapeutic antibody discovery.
Applications of Phage Display
Phage display is a rapidly evolving technology that has been used to support a range of applications depending on the nature of the phage display library.
Epitope Mapping
When an antibody recognises a specific antigen, the binding region is referred to as the epitope.
Knowledge of antigenic epitopes is valuable for the development of effective antibody reagents for research use and therapeutics. Moreover, epitope mapping has significant utility in vaccine development as it can help elucidate immune responses.
Receptor and Ligand Identification
Phage display is an efficient method to determine which proteins or peptides bind specifically to predefined targets.
This facilitates the study of receptor-ligand interactions. Furthermore, it sheds light on cellular signalling pathways through the identification of key inhibitors, agonists and antagonists.
Protein-Protein Interaction Studies
Virtually all biological processes are mediated by protein-protein interactions.
Phage display provides a means of evaluating complex inter-protein relationships and identifying both known and novel binding partners.
Recombinant Antibody Production
Antibody phage display is regarded by many as the gold standard in recombinant antibody production.
By screening large numbers of antibody-displaying phages against a target antigen, phages expressing antibodies specific to that target can be identified quickly.
One method of producing a library of antibody-displaying phage is to immunise an animal, isolate B-cells, extract mRNA and synthesise cDNA encoding antibody single-chain variable regions (scFv) for cloning into phagemid vectors.
It is also possible to purchase pre-synthesised libraries consisting of many different antibody scFv genes.
Directed Evolution of Proteins
Directed evolution introduces desirable features into an existing protein through the acquisition of mutations.
Using a phage display library composed of multiple protein variants, researchers can identify mutations with the required characteristics.
Drug Discovery
Phage display has widespread utility within drug discovery.
Not only can it facilitate the identification of peptide ligands for therapeutic targets, it can also provide a launch point for drug discovery efforts and help researchers understand how these biomolecules may cross-react with other proteins.
Research groups continue to use phage display to identify antibody fragments suitable for targeted delivery of therapeutic payloads.
Why Does This Matter?
Many of the antibodies, proteins, and targeting molecules used throughout modern biotechnology research and drug development originate from technologies such as phage display.
Its versatility is one of the reasons why it remains a core discovery platform more than three decades after its introduction.
Practical Example: Antibody Discovery Using Phage Display
A biotechnology company developing a therapeutic antibody against a novel cancer target may begin by screening a synthetic antibody library containing billions of variants.
Following several rounds of biopanning, antibody candidates with the highest affinity and specificity can be isolated, sequenced, and reformatted into full-length antibodies for further evaluation.
This approach significantly reduces discovery timelines and allows researchers to identify lead candidates without relying solely on animal immunisation.
Future Directions for Phage Display
Phage display continues to evolve alongside advances in synthetic biology, next-generation sequencing, antibody engineering, and computational protein design.
Researchers are increasingly combining phage display with high-throughput sequencing to better understand library diversity and selection dynamics. At the same time, synthetic antibody libraries continue to expand the range of therapeutic targets that can be addressed.
More than three decades after its introduction, phage display remains one of the most important technologies in modern biotechnology.
Contact us
To streamline phage display and accelerate workflows, it is wise to partner with an experienced provider of phage display services.
A trusted partner can help advance your research by facilitating new insight. They can also offer a comprehensive understanding of phage display library construction, including detailed knowledge of different phage display systems and technologies to best meet your needs.
With many years of experience, Pivotal Scientific can direct you to the most appropriate experts for your phage display requirements.
If you would like to find out more or get in touch, please contact us today!
References
- Smith GP. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science. 1985;228(4705):1315–1317.
- McCafferty J, Griffiths AD, Winter G, Chiswell DJ. Phage antibodies: filamentous phage displaying antibody variable domains. Nature. 1990;348:552–554.
- Nobel Prize Outreach AB. The Nobel Prize in Chemistry 2018: Directed Evolution of Enzymes and Phage Display of Peptides and Antibodies.
- Frenzel A, Kügler J, Helmsing S, Meier D, Schirrmann T, Hust M. Phage display-derived human antibodies in clinical development and therapy. mAbs. 2017;9(2):138–152.
- Alfaleh MA, Alsaab HO, Mahmoud AB, Alkayyal AA, Jones ML, Mahler SM, Hashem AM. Phage Display Derived Monoclonal Antibodies: From Bench to Bedside. Molecules. 2020;25(17):3949.
- Pande J, Szewczyk MM, Grover AK. Phage display: concept, innovations, applications and future. Biotechnology Advances. 2010;28(6):849–858.
- Winter G, Griffiths AD, Hawkins RE, Hoogenboom HR. Making antibodies by phage display technology. Annual Review of Immunology. 1994;12:433–455.
Phage display is a molecular biology technique that displays peptides, proteins, or antibody fragments on the surface of bacteriophages for screening and selection.
The gene encoding a protein is fused to a phage coat protein gene, allowing the protein to be displayed on the phage surface while retaining the encoding DNA inside the particle.
Phage display enables rapid identification of high-affinity antibody candidates and supports entirely in vitro antibody selection workflows.
Phage display libraries are collections of billions of peptide, protein, or antibody variants that can be screened against a target molecule.
Phage display can be used to identify monoclonal antibodies, antibody fragments such as scFvs and Fabs, and fully human antibody candidates.
Many phage display libraries contain billions of unique variants, enabling extensive screening diversity.
Yes. Phage display is widely used throughout therapeutic antibody discovery and development programmes.
